A Pharmacokinetic-pharmacodynamic Study of Early Rickettsia Clearance in Murine Typhus or Scrub Typhus Patients Treated With Doxycycline or Azithromycin (PHARC)
Infectious Disease, Therapeutics
About this trial
This is an interventional treatment trial for Infectious Disease focused on measuring Scrub Typhus, Typhus, Endemic Flea-Borne
Eligibility Criteria
Inclusion Criteria: Age above or equal 15 years Able to take oral medication Agrees to stay in hospital for at least 72 hours and to attend for scheduled follow up visits Written informed consent to participate in the study Exclusion Criteria: Pregnancy (urine pregnancy test to be performed on women of childbearing age) Previous allergic reaction to doxycycline or azithromycin Received more than one dose of chloramphenicol, doxycycline, tetracycline, fluoroquinolones, rifampicin or azithromycin during the preceding week
Sites / Locations
- Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU)
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Doxycycline
Azithromycin
Doxycycline (Vibramycin, 100-mg film-coated tablets; Pfizer)) 200-mg loading dose, followed by 100 mg every 12 hours for 3 days.
Azithromycin (Zithromax, 250-mg capsules; Pfizer) with a 500-mg loading dose, followed by 250 mg every 24 hours for 2 days. This will be followed by three days of doxycycline at the dose in A.